With a year-over-year growth in debt of 446.64%, Rockwell Medical Inc's debt growth rate surpasses 95.99% of about US stocks.
The volatility of Rockwell Medical Inc's share price is greater than that of 86.12% US stocks with at least 200 days of trading history.
Rockwell Medical Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -66.81%, greater than the shareholder yield of only 5.28% of stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Rockwell Medical Inc are WTT, NSPR, CPIX, RWLK, and PRCP.
RMTI's SEC filings can be seen here. And to visit Rockwell Medical Inc's official web site, go to www.rockwellmed.com.
Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. The company was founded in 1995 and is based in Wixom, Michigan.
Global Hypercalcemia Treatment Market Overview: The Hypercalcemia Treatment Market has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Hypercalcemia Treatment Market size to maintain the average annual growth rate of 5.42% from $169
Rockwell Medical (RMTI) enters into securities purchase agreements with several healthcare-focused and other institutional investors to purchase ~23M of its shares and short-term warrants. The combined purchase price for one share of common stock and a warrant is $1.51. The warrants have an exercise price of $1.80 per share, will be...
Rockwell Medical (RMTI) has entered into an exclusive license agreement with Jeil Pharmaceutical, for the rights to commercialize Triferic in South Korea. Under the terms, Jeil will be the exclusive development and commercialization partner for Triferic in South Korea and Rockwell Medical will supply the product to Jeil. A Joint...
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDA...